Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Powered by GeneDx Infinity™ with unparalleled scale and diversity, GeneDx fuels breakthrough scientific research and delivers t...
Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Equal-Weight and raises the price target...
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $15...
Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $115 to $170.
BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $140 to $165.
GeneDx Hldgs (NASDAQ:WGS) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.42 by ...
GeneDx Holdings (NASDAQ:WGS) raises FY2025 sales outlook from $400.000 million-$415.000 million to $425.000 million-$428.000 mi...
